OTHER INFORMATION
−Removed: During the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.
+Added: During the quarterly period covered by this report, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.
Incorporation by Reference
1 unchanged sentence
Number Filing Filing Date File No.
−Removed: Amended Non-Employee Director Compensation Policy, effective March 12, 2026
−Removed: 10.2 First Amendment to Loan Agreement, dated January 5, 2026, among the Registrant, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership.
−Removed: March 2, 2026
−Removed: Consulting Agreement by and between the Company and Andrew Grethlein, effective October 16, 2025.
−Removed: E mployment Agreement by and between the Company and Timothy Williams, effective April 13, 2026.
+Added: 10.1* 2 018 Equity Incentive Plan, as amended
+Added: 10.1 8-K 5/27/2026 000-20859
+Added: 10.2+* 2026 Severance Plan, effective as of June 25, 2026
+Added: 10.3* Employment Agreement by and between the Company and Timothy Williams, effective April 13, 2026.
+Added: 10.4 10-Q 5/6/2026 000-20859
Certification of Chief Executive Officer pursuant to Form of Rule 13a‑14(a), as adopted pursuant to Section 302(a) of the Sarbanes‑Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002.**
−Removed: 101 The following materials from the Registrant’s March 31, 2026 Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 formatted in Inline Extensible Business Reporting Language (iXBRL) include:
−Removed: (i) Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2026 and 2025, (iii) Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2026 and 2025, (iv) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025 and (v) Notes to Condensed Consolidated Financial Statements.
+Added: 101 The following materials from the Registrant’s June 30, 2026 Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 formatted in Inline Extensible Business Reporting Language (iXBRL) include:
+Added: (i) Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2026 and 2025, (iii) Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2026 and 2025, (iv) Condensed Consolidated Statements of Cash Flows for the three and six months ended June 30, 2026 and 2025 and (v) Notes to Condensed Consolidated Financial Statements.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
5 unchanged sentences
GERON CORPORATION
+Added: August 5, 2026
/s/ MICHELLE ROBERTSON
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.